Objective: Video-assisted thoracoscopic surgical (VATS) lung biopsy is frequently used in the diagnosis of parenchymal lung disease. However, there is still debate over the need for routine use of an intercostal chest drain after this procedure. This study aimed to evaluate the necessity of positioning an intercostal chest drain as an integral part of VATS lung biopsy. Methods: Data from VATS lung biopsies performed over a 5-year period were retrospectively analysed. Patients in whom there was evidence of air leak intra-operatively following lung biopsy were excluded. Patients in whom no air leak was detected on testing were included in this study. A chest drain was inserted solely according to the surgeons' practice. Results: This study included 175 patients. Of these, 82 patients had an intercostal chest drain positioned during the VATS procedure and 93 did not. There were no significant differences between the two groups in terms of mean (standard deviation (SD)), age (54.4 (14.9) vs 55.8 (13.5) years, p = 0.58), gender (63% vs 59% males, p = 0.56) or side of procedure (45% vs 56% right side, p = 0.22). One patient in the 'no drain' group developed a clinically significant pneumothorax 24 h after surgery and required a drain to be inserted. There was also no significant difference between the two groups in the incidence of radiologically detected pneumothorax immediately post-procedure (23% vs 20%, p = 0.66) or on postoperative day 1 (26% vs 20%, p = 0.63). There was no significant difference in the incidence of pneumothorax on follow-up (at 4-6 weeks) chest radiograph (10% vs 7%, p = 0.61). In all cases, the pneumothoraces were small and not clinically significant. However, there was a significant difference in the median (inter-quartile range (IQR)) length of stay between the two groups (3 (2,4) vs 2 (1,3) days, respectively, p < 0.001). Conclusions: The routine use of an intercostal chest drain after VATS lung biopsy unnecessarily increases the length of hospital stay without reduction in the incidence of pneumothorax. #
Introduction
The role of video-assisted thoracoscopic surgical (VATS) lung biopsy in the diagnosis of interstitial lung diseases is well recognised [1, 2] . The routine placement of an intercostal chest drain has been an established part of VATS lung biopsy, although evidence for its use is lacking. Sienel et al. found that early removal of the intercostal chest drain after VATS lung biopsy reduced pain without an increase in postoperative complications [3] , whilst Watanabe et al. found that omission of the intercostal drain in a carefully selected group of patients undergoing thoracoscopic wedge resection of the lung did not increase postoperative morbidity [4] . A randomised controlled trial by Luckraz et al. concluded that routine chest drain placement at lung biopsy was unnecessary unless an air leak was detected at the time of operation [5] .
The aim of this retrospective analysis was to determine the necessity of an intercostal drain in a larger group of patients undergoing VATS lung biopsy and the impact of its use on the length of stay in the hospital.
Materials and methods
The data of 175 patients undergoing VATS lung biopsy between May 2003 and January 2008 were retrospectively analysed. The biopsy was performed under general anaesthesia and single-lung ventilation. A three-port technique was used and the biopsy was taken using the endostapling system (Endo GIA [Autosuture, Tyco Healthcare, Norwalk, CT, USA]). A single biopsy was performed from an area of the lung, which, on computed tomography (CT) scan, was representative of various stages of the disease process.
After the biopsy, the lung was tested for air leak. The technique employed for testing the lung has been previously described [5] . Briefly, after biopsy, the lung was re-expanded with sustained inflation to an airway pressure of 30 cm H 2 O by the anaesthetist for 1 min. An air leak was diagnosed by persistent bubbling down an 8-mm Ryle's nasogastric tube placed in the posterior pleural cavity with the other end placed into a small water-filled container.
If an air leak was observed, then a chest drain was used and the patient was excluded from this study. Patients in whom no air leak was detected were included in the study group. The usage of an intercostal chest drain in these patients was solely at the discretion of the surgeon's usual practice. At that time, there was no level 1 evidence to inform practice.
The primary end points for the study were the incidence of clinically significant pneumothorax and in-hospital length of stay. The incidence of pneumothorax (detected radiologically with and without clinical effect) was recorded immediately postoperatively, at 24 h postoperatively prior to discharge and at follow-up 6 weeks after the procedure. The clinical significance of postoperative pneumothorax and requirement for drainage of the pneumothorax with a chest drain was also recorded.
Preoperative data collected included age, sex and side of VATS lung biopsy. Postoperative data included incidence of pneumothorax on radiograph and its clinical significance in the immediate postoperative phase (within 1 h of operation), 24 h and 6 weeks postoperatively in addition to the need for insertion of an intercostal chest drain postoperatively. The final lung histology was also recorded.
Statistical analysis
Data are expressed as percentages (gender, side biopsied and histology), mean with standard deviation (age) and median with inter-quartile range (IQR; in-hospital stay). The groups were then compared using chi-squared, MannWhitney U-test and Student's t-test, respectively. The final histology of the lung biopsy for the patients in each group was compared using chi-squared test. A p value of <0.05 was deemed to show significant difference. Data were analysed using SPSS 15 software package.
Results
Approximately 10% of patients undergoing VATS lung biopsy at our institution had a proven intra-operative air leak and were therefore excluded from this analysis. The remaining 175 patients were included as no air leak was demonstrated during testing. An intercostal chest drain was positioned in 82 patients (as per surgeons' practice) and 93 patients did not have a chest drain placed intra-operatively.
There were no significant differences between the two groups in terms of mean (standard deviation (SD)), age (54.4 (14.9) vs 55.8 (13.5) years, p = 0.58), gender (63.4% vs 59.1% males, p = 0.56) or side of procedure (45% vs 56% right side, p = 0.22). The preoperative demographics are shown in Table 1 .
The histology obtained from the VATS biopsy was available for 167 patients and is shown in Table 2 . There was no significant difference between the two groups with respect to the lung pathology ( p = 0.30, chi-squared test).
There was also no significant difference between the two groups in the incidence of radiologically detected pneumothorax immediately post-procedure (23% vs 20%, p = = 0.66) or on postoperative day 1 (26% vs 20%, p = 0.63). Likewise, there was no significant difference in the incidence of pneumothorax on follow-up (at 4-6 weeks) chest radiograph (10% vs 7%, p = 0.61). These radiologically detected pneumothoraces were relatively small in size (<5%) and had no clinical effect on the patients.
One of the patients who did not have an intercostal chest drain inserted at the time of the procedure did require a chest drain 24 h postoperatively for a symptomatic significant pneumothorax.
There was a significant difference in the median (IQR) length of stay between the two groups (3 (2,4) vs 2 (1,3) days, respectively, p < 0.001). The incidence and length of stay is shown in Table 1 . None of these patients required hospital readmission for pneumothorax treatment after discharge.
Discussion
The need for routine placement of an intercostal chest drain during VATS lung biopsy is controversial. The present study used a novel technique previously reported in a randomised controlled trial from our institution to determine the presence of an air leak and the necessity for intercostal chest drain placement in those patients in whom no air leak was detected. In our experience, the positioning of an intercostal chest drain at VATS lung biopsy is associated with a significantly longer duration of in-hospital length of stay with no reduction in the incidence of clinically significant pneumothorax. Therefore, we propose that routine placement of an intercostal chest drain at VATS lung biopsy is unnecessary if no air leak is detected at the time of operation. In approximately 10% of patients, an air leak is present following VATS lung biopsy and can be detected using the novel Ryle's tube technique. In these patients an intercostal chest drain should still be routinely placed during the procedure.
Blewett et al. showed that selective intercostal drain placement on the basis of air leak enabled open lung biopsy to be performed as an outpatient procedure [6] . In the present study, the majority of patients in whom an intercostal drain was not placed were discharged within 24 h of operation. Patients in whom a chest drain is placed intra-operatively require surgical review to action the drain removal, the availability of nursing staff to remove the drain, a post-drain chest radiograph, a mobility-withoutdiscomfort assessment by the physiotherapist and a final surgical review to confirm that discharging the patient home is safe, resulting in a longer length of stay. By comparison, the no drain group require only a surgical review to assess whether they are safe for discharge. This raises the possibility of VATS lung biopsy being offered as a day-case procedure, with potential cost savings. Based on cost calculations within our department, we have estimated that the shorter length of stay in the no drain group equates to a £800 saving per patient per day.
In addition to reduced stay and potential cost savings, we also observed that the 'no drain' group appeared to experience less pain and mobilised more rapidly postprocedure; but due to the retrospective nature of the study there was an incomplete data set for the whole group. However, a previous report by Sienel et al. [3] has confirmed that the need for analgesia is reduced in the absence of an intercostal drain. Further randomised controlled studies are required to assess this aspect of potential clinical benefit.
The patients in the present study were found at histological examination of their lung biopsies to have a wide range of lung pathology including carcinoma, sarcoid, emphysematous lung, infective pathology, bronchiolitis obliterans with organising pneumonia and other conditions such as hamartomas and Wegener's granulomatosis. There was no significant difference in the proportion of these different disease processes between the two groups. Therefore, the technique for air leak testing and the decision to omit intercostal drain placement on the basis of this can be applied across a wide range of lung conditions.
One surprising outcome of the present study was the incidence of post-VATS pneumothorax. We found that approximately one in five patients had a pneumothorax postoperatively. However, these are radiologically reported chest radiographs and these pneumothoraces were relatively small in size (less than 5%) and were evident in both groups equally. The vast majority of pneumothoraces were clinically insignificant and only one patient in the 'no drain' group required insertion of a chest drain 24 h postoperatively for a clinically significant pneumothorax.
In conclusion, routine placement of an intercostal chest drain in those patients with no air leak at the time of VATS biopsy is unnecessary and is associated with a longer inhospital stay. The Ryle's tube technique of detecting air leak is a reliable and cost-effective way of determining the need for intercostal chest drain insertion post-VATS lung biopsy across a range of benign and malignant lung conditions. It is hoped that this technique will enable the presence of an air leak to be more confidently assessed and enable the omission of a chest drain in those patients without an air leak, with potential cost savings and clinical benefit. really keeping them postoperatively. The majority of our patients went home within 24 hours of their VATS biopsy, the ones who didn't have a drain, so I think it's definitely possible.
Dr A. Lerut (Leuven, Belgium): It is not because you are inserting a drain, reason per se that the patients stay longer in the hospital. So what was the reason that the patients in the group with drains stayed one day longer?
Dr Satherley: This is an evolutionary process, so as time has gone on, we have learned that we can take the drains that are placed out sooner. It may be that at the start of the process people were staying longer because when a patient has an intervention like a drain, there is more tendency perhaps to keep them.
Dr Luckraz: I'm one of the authors. Basically it's logistic. By the time the chest drain is reviewed the next morning and a decision is made for the drain to come out, and whoever works in the UK probably knows that the drain doesn't come out straightaway, by the time it comes out and then you have a repeat chest X-ray, it's very late in the day. It would have been the next day. So it's all logistic.
Dr S. Halezeroglu (Istanbul, Turkey): When you were presenting your paper, you presented some literature data, and the conclusion of the literature data was that no drain can be used in selected patients only, but when you make your conclusion, you say that it shouldn't be used in any patients at all. So you are moving one step ahead of the literature at the moment. But when we think about all the patients who we perform open lung biopsy, these patients have diffuse interstitial lung disease and severe respiratory insufficiency in some patients. So if we do not insert any chest tube in any patient with an open lung biopsy, it can be complicated. I think we have to change the conclusion and say that in some selected patients it cannot be used, but not all patients.
Dr Satherley: Maybe there's a different population that are having the VATS approach than the open approach, but looking at our results, we can see that 15% of our patients had a malignancy. So our data includes both benign and malignant disease. The other question is whether it can be applied to emphysematous lung, and actually 8% of our patients had emphysematous disease. So it does have wide application. We had patients with malignancy, benign disease, interstitial disease -a big variety. I think that was one of the things about this study, that it was larger than the previous randomised controlled trials and we were able to illustrate it in a large group of patients with more diverse disease.
